Mar 7 |
7 Short-Squeeze Stocks That Could Send the Bears Into Panic-Mode
|
Mar 6 |
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
|
Mar 1 |
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
|
Feb 27 |
Why Biomea Fusion Is A 'Hold': A Bet On Diabetes And Oncology Research
|
Feb 19 |
Feeling Shut Out? 3 Sizzling Stocks and the Pull-Back Prices to Watch For
|
Jan 25 |
Alaska Air Posts Upbeat Earnings, Joins Xerox, United Rentals And Other Big Stocks Moving Higher On Thursday
|
Jan 9 |
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
|
Jan 8 |
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
|
Jan 3 |
Jim Cramer Says Move On From This Energy Stock: 'It's Moved Too Much'
|
Jan 2 |
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
|